Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the evolving role of CAR-T therapy in the treatment of chronic lymphocytic leukemia (CLL), which has lagged behind other B-cell malignancies. Dr Jain describes the renewed interest in CAR-T for patients with CLL who relapse after BCL2 and BTK inhibitors, and highlights a trial investigating lisocabtagene maraleucel (liso-cel). This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.